(HCC)[33], andcolon cancertissues[34]. Of note, ABCA1 overexpression was found to reduce the proliferation rate of colon cancer HCT116 cells, while silencing of ABCA1 promoted the proliferation and inhibited theapoptosisof colon cancer LDL1 cells[25]. Low levels of ABCA1 have also been ...
In the endeavor to construct the PDOTs model for ICC, challenges were encountered stemming from the distinctive cell types and microenvironmental compositions that differentiate ICC from HCC. Consequently, the success rate for ICC was markedly below that of HCC. As a result, the PDOTs cohort in ...
随后的CHANCE2201研究为比较TACE联合靶免(802例)对比单纯靶免(442例)在晚期HCC(BCLC C期/CNLC IIIa期)的有效性及安全性的RWS, 采用模拟目标试验框架(Target Trial Emulation Framework)分析。结果显示,TACE联合靶免治疗组中位OS及PFS分...
获中国NMPA批准,用于不可切除或转移性肝细胞癌(HCC)的一线治疗;2024年4月24日,获批与依托泊苷+铂类化疗联合,用于广泛期小细胞肺癌(ES-SCLC)的一线治疗;2024年4月30日,获批与铂类化疗药+氟尿嘧啶类药物联用,一线治疗局部晚期不可切...
The breast cancer resistance protein (BCRP/ABCG2) is a member of the G-subfamiliy of the ATP-binding cassette (ABC)-transporter superfamily. This half-transporter is assumed to function as an important mechanism limiting cellular accumulation of various
乙肝病毒DNA(cccDNA)在肝脏中的检出率较高。肝硬化发病前HBsAg的丢失与肝硬化、失代偿期和肝癌的风险降低和生存率的提高有关。然而,如果在HBsAg丢失前肝硬化已经发展,患者仍有发生肝癌的风险,因此应继续进行HCC监测。免疫抑制可能导致这些患者的乙肝病毒重新激活。
Radiofrequency-Assisted Versus Clamp-Crushing Parenchyma Transection in Cirrhotic Patients with Hepatocellular Carcinoma: A Randomized Clinical Trial Surgical resection remains the optimal therapy for cirrhotic patients with hepatocellular carcinoma (HCC) that are not suitable for liver transplantation (... M...
原发性肝癌(Hepatocellular carcinoma, HCC)在世界最常见的肿瘤中排名第五位,其发病率正日益全球化1。大多数的肝细胞癌患者确诊时已到晚期,因而肝移植、肝切除或射频消融手段也未能有效。SHARP研究与ORIENTAL研究表明,索拉非尼作为一种多靶点激酶抑制剂,能够延长晚期HCC患者的总体生存2,3。因而,索拉非尼是目前唯一被...
Cisplatin (CDDP) is an anticancer agent that is commonly used in hepatic arterial infusion (HAI) chemotherapy for hepatocellular carcinoma (HCC). This stud... A Osaki,T Suda,K Kamimura,... - 《Cancer Medicine》 被引量: 59发表: 2013年 Chemotherapy for hepatocellular carcinoma with portal hype...
22 Results of a Cell Counting Kit-8 (CCK-8) assay showed that the 50% inhibitory concentration (IC50) value for gefitinib in PC9/GR cells was 1.77 μM, with a 35.40-fold increase relative to that in PC9 cells (0.05 μM), and the IC50 value for gefitinib in HCC827/GR cells was ...